Also...
- Share via
The government charged that the firm now known as Aventis illegally paid Andrx Corp. to keep a competing drug for high blood pressure and chest pains off the market. The Federal Trade Commission said it had settled similar charges that Abbott Laboratories paid Novartis unit Geneva Pharmaceuticals Inc. to keep a competing drug off the market for Hytrin, used to treat high blood pressure and enlarged prostates. The FTC said Aventis, known as Hoechst Marion Roussel then, paid Andrx to keep a competitor to Cardizem CD off the market for two years. The companies denied wrongdoing. The companies are not expected to be fined but will be ordered to cease the practice.
Guide to Our Staff: Need to reach Business section reporters or editors? A guide to the section’s staff can be found at http://vinapk.com/bizstaff.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.